---
title: "Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292111129.md"
description: "On July 8, 2026, Candel Therapeutics, Inc. revealed that the Compensation Committee of its Board of Directors awarded Mark Sims, the new Chief Commercial Officer, stock options to buy 285,000 shares of common stock at an exercise price of $10.03 per share. The grant matches the closing price of Candel's common stock on The Nasdaq Global Market on July 6, 2026. Candel is a Nasdaq-listed clinical-stage biopharmaceutical firm with a focus on developing multimodal immunotherapies for enhancing cancer patient outcomes."
datetime: "2026-07-08T20:06:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292111129.md)
  - [en](https://longbridge.com/en/news/292111129.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292111129.md)
generator: "portal-rs"
---

# Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

On July 8, 2026, Candel Therapeutics, Inc. revealed that the Compensation Committee of its Board of Directors awarded Mark Sims, the new Chief Commercial Officer, stock options to buy 285,000 shares of common stock at an exercise price of $10.03 per share. The grant matches the closing price of Candel's common stock on The Nasdaq Global Market on July 6, 2026. Candel is a Nasdaq-listed clinical-stage biopharmaceutical firm with a focus on developing multimodal immunotherapies for enhancing cancer patient outcomes.

### Related Stocks

- [CADL.US](https://longbridge.com/en/quote/CADL.US.md)

## Related News & Research

- [Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Recommendation of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/298423186.md)
- [Candel Therapeutics director Martine Zimmermann files initial beneficial ownership statement](https://longbridge.com/en/news/298640477.md)
- [Candel Therapeutics CEO Paul Peter Tak disposes of common shares worth $3,164,815.85](https://longbridge.com/en/news/298773699.md)
- [Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors | CADL Stock News](https://longbridge.com/en/news/298592512.md)
- [CADL: BLA submission for aglatimogen in prostate cancer is planned by year-end, with key data updates ahead](https://longbridge.com/en/news/298642995.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**